Reunion Neuroscience

We are excited to share our recent article in Contemporary OB/GYN featuring Sheryl Kingsberg, PhD, discussing our ongoing RECONNECT Phase 2 trial (www.ppdreconnectstudy.com) to help bring a single dose #pyschedelic treatment to women suffering from moderate to severe #postpartumdepression. Read full article here: https://lnkd.in/eHJwXBaD

We are proud to acknowledge today as #WorldMentalHealthDay, a global initiative to raise awareness and break the stigma around mental health. This initiative underscores our mission at #ReunionNeuroscience to advance next-generation therapies that address mental health conditions and improve the lives of patients and families impacted by the growing mental health crisis. To support this mission, we are currently enrolling patients in our RECONNECT Phase 2 trial evaluating our lead candidate RE104 for the treatment of moderate to severe postpartum depression. To learn more about the RECONNECT trial and patient eligibility, please visit: www.ppdreconnectstudy.com

Today we announced a new partnership with the Seleni Institute, a nonprofit organization that provides treatment and training for #maternalmentalhealth and wellness issues. This partnership furthers Reunion’s commitment to developing our lead psychedelic investigational product, RE104, for women suffering from moderate to severe #postpartumdepression through our RECONNECT Phase 2 trial. To learn more about the trial and its eligibility requirements, please visit: www.ppdreconnectstudy.com. To learn more about Seleni and to apply to the scholarship program, please visit: seleni.org/scholarship.

Our President and CEO, Greg Mayes, was featured in the Wall Street Journal discussing Reunion Neuroscience’s $103 million Series A financing for our ongoing RECONNECT Phase 2 trial (www.ppdreconnectstudy.com) to help bring a novel treatment to women suffering from moderate to severe #postpartumdepression. Read full article here: https://lnkd.in/gAre8cwr

Today is National Women’s Health and Fitness Day, a day to celebrate the importance of promoting health awareness and fitness for all women, including new mothers. Reunion is committed to developing a single dose treatment option for women suffering from moderate to severe #postpartumdepression through its RECONNECT Phase 2 trial that offers eligible women the opportunity to evaluate the safety and efficacy of a next-generation psychedelic molecule. To learn more about the RECONNECT trial, please visit: www.ppdreconnectstudy.com

We are pleased to welcome Mark Pollack, M.D. as our new Chief Medical Officer at Reunion Neuroscience. With over nearly four decades of experience in neuroscientific research and pharmaceutical development, Dr. Pollack brings a wealth of knowledge and leadership to Reunion at a pivotal time as we advance the RECONNECT Phase 2 trial, continuing our mission to deliver therapies for patients with mental health disorders. To learn more about the RECONNECT trial, please visit: www.ppdreconnectstudy.com

Today we announced a new partnership with “Is Mom OK?” in recognition of #maternalsuicidepreventionmonth. This unprecedented initiative, launched by Cherished Mom, a renowned nonprofit organization dedicated to transforming the landscape of #maternalmentalhealth, aims to educate and drive support for moms, with a specific focus on addressing maternal suicide and mortality. This partnership furthers our commitment to patients and families suffering from #postpartumdepression and follows the recent initiation of the RECONNECT Phase 2 trial that evaluates our lead molecule RE104 in mothers with moderate to severe postpartum depression. To learn more about the trial, please visit: www.ppdreconnectstudy.com

We are pleased to announce that the first patient has been dosed in our RECONNECT Phase 2 clinical trial of RE104 for the treatment of #postpartumdepression. This marks a significant clinical milestone in the development of our novel, fast-acting, single-dose, #psychedelic therapies to address underserved #mentalhealthdisorders. Learn more: https://bit.ly/3WyXowI

We are thrilled to share our recent article in Psychiatric Times highlighting the clinical development of RE104, a proprietary, serotonergic #psychedelic drug candidate for underserved #mentalhealth disorders, beginning with #postpartumdepression. Thank you to Reunion team members, Robert Alexander, Jasna Hocevar-Trnka, Nathan Bryson, PhD and Beatrix Taylor for their incredible work on this article: https://bit.ly/4eA0eZn

We are excited to announce the publication of the results of preclinical studies in ACS Chemical Neuroscience demonstrating the potential of RE104 for development in depressive disorders. Reunion is advancing RE104, a proprietary, clinical-stage serotonergic #psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders, beginning with #postpartumdepression. Read the press release: https://bit.ly/3wFJkY4